View in EDS HTML Full Text PDF Full Text

Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs.

Saved in:
Bibliographic Details
Title: Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs.
Authors: Barbosa, Carolina (AUTHOR), Fraser, Hannah (AUTHOR), Hoerger, Thomas J. (AUTHOR), Leib, Alyssa (AUTHOR), Havens, Jennifer R. (AUTHOR), Young, April (AUTHOR), Kral, Alex (AUTHOR), Page, Kimberly (AUTHOR), Evans, Jennifer (AUTHOR), Zibbell, Jon (AUTHOR), Hariri, Susan (AUTHOR), Vellozzi, Claudia (AUTHOR), Nerlander, Lina (AUTHOR), Ward, John W. (AUTHOR), Vickerman, Peter (AUTHOR)
Source: Addiction. Dec2019, Vol. 114 Issue 12, p2267-2278. 12p. 2 Charts, 2 Graphs.
Subjects: Hepatitis C treatment, Intravenous drug abusers, Hepatitis C prevention, Antiviral agents, Cost effectiveness, Medical care costs, Needle exchange programs
Abstract: Aims: To examine the cost‐effectiveness of hepatitis C virus (HCV) treatment of people who inject drugs (PWID), combined with medication‐assisted treatment (MAT) and syringe‐service programs (SSP), to tackle the increasing HCV epidemic in the United States. Design HCV transmission and disease progression models with cost‐effectiveness analysis using a health‐care perspective. Setting: Rural Perry County, KY (PC) and urban San Francisco, CA (SF), USA. Compared with PC, SF has a greater proportion of PWID with access to MAT or SSP. HCV treatment of PWID is negligible in both settings. Participants: PWID data were collected between 1998 and 2015 from Social Networks Among Appalachian People, U Find Out, Urban Health Study and National HIV Behavioral Surveillance System studies. Interventions and comparator: Three intervention scenarios modeled: baseline—existing SSP and MAT coverage with HCV screening and treatment with direct‐acting antiviral for ex‐injectors only as per standard of care; intervention 1—scale‐up of SSP and MAT without changes to treatment; and intervention 2—scale‐up as intervention 1 combined with HCV screening and treatment for current PWID. Measurements Incremental cost‐effectiveness ratios (ICERs) and uncertainty using cost‐effectiveness acceptability curves. Benefits were measured in quality‐adjusted life‐years (QALYs). Findings For both settings, intervention 2 is preferred to intervention 1 and the appropriate comparator for intervention 2 is the baseline scenario. Relative to baseline, for PC intervention 2 averts 1852 more HCV infections, increases QALYS by 3095, costs $21.6 million more and has an ICER of $6975/QALY. For SF, intervention 2 averts 36 473 more HCV infections, increases QALYs by 7893, costs $872 million more and has an ICER of $11 044/QALY. The cost‐effectiveness of intervention 2 was robust to several sensitivity analysis. Conclusions: Hepatitis C screening and treatment for people who inject drugs, combined with medication‐assisted treatment and syringe‐service programs, is a cost‐effective strategy for reducing hepatitis C burden in the United States. [ABSTRACT FROM AUTHOR]
Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 139764987
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Barbosa%2C+Carolina%22">Barbosa, Carolina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fraser%2C+Hannah%22">Fraser, Hannah</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hoerger%2C+Thomas+J%2E%22">Hoerger, Thomas J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leib%2C+Alyssa%22">Leib, Alyssa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Havens%2C+Jennifer+R%2E%22">Havens, Jennifer R.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Young%2C+April%22">Young, April</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kral%2C+Alex%22">Kral, Alex</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Page%2C+Kimberly%22">Page, Kimberly</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Evans%2C+Jennifer%22">Evans, Jennifer</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zibbell%2C+Jon%22">Zibbell, Jon</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hariri%2C+Susan%22">Hariri, Susan</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vellozzi%2C+Claudia%22">Vellozzi, Claudia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Nerlander%2C+Lina%22">Nerlander, Lina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ward%2C+John+W%2E%22">Ward, John W.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vickerman%2C+Peter%22">Vickerman, Peter</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Addiction%22">Addiction</searchLink>. Dec2019, Vol. 114 Issue 12, p2267-2278. 12p. 2 Charts, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Hepatitis+C+treatment%22">Hepatitis C treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Intravenous+drug+abusers%22">Intravenous drug abusers</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatitis+C+prevention%22">Hepatitis C prevention</searchLink><br /><searchLink fieldCode="DE" term="%22Antiviral+agents%22">Antiviral agents</searchLink><br /><searchLink fieldCode="DE" term="%22Cost+effectiveness%22">Cost effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+care+costs%22">Medical care costs</searchLink><br /><searchLink fieldCode="DE" term="%22Needle+exchange+programs%22">Needle exchange programs</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Aims: To examine the cost‐effectiveness of hepatitis C virus (HCV) treatment of people who inject drugs (PWID), combined with medication‐assisted treatment (MAT) and syringe‐service programs (SSP), to tackle the increasing HCV epidemic in the United States. Design HCV transmission and disease progression models with cost‐effectiveness analysis using a health‐care perspective. Setting: Rural Perry County, KY (PC) and urban San Francisco, CA (SF), USA. Compared with PC, SF has a greater proportion of PWID with access to MAT or SSP. HCV treatment of PWID is negligible in both settings. Participants: PWID data were collected between 1998 and 2015 from Social Networks Among Appalachian People, U Find Out, Urban Health Study and National HIV Behavioral Surveillance System studies. Interventions and comparator: Three intervention scenarios modeled: baseline—existing SSP and MAT coverage with HCV screening and treatment with direct‐acting antiviral for ex‐injectors only as per standard of care; intervention 1—scale‐up of SSP and MAT without changes to treatment; and intervention 2—scale‐up as intervention 1 combined with HCV screening and treatment for current PWID. Measurements Incremental cost‐effectiveness ratios (ICERs) and uncertainty using cost‐effectiveness acceptability curves. Benefits were measured in quality‐adjusted life‐years (QALYs). Findings For both settings, intervention 2 is preferred to intervention 1 and the appropriate comparator for intervention 2 is the baseline scenario. Relative to baseline, for PC intervention 2 averts 1852 more HCV infections, increases QALYS by 3095, costs $21.6 million more and has an ICER of $6975/QALY. For SF, intervention 2 averts 36 473 more HCV infections, increases QALYs by 7893, costs $872 million more and has an ICER of $11 044/QALY. The cost‐effectiveness of intervention 2 was robust to several sensitivity analysis. Conclusions: Hepatitis C screening and treatment for people who inject drugs, combined with medication‐assisted treatment and syringe‐service programs, is a cost‐effective strategy for reducing hepatitis C burden in the United States. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Addiction is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=139764987
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/add.14731
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 2267
    Subjects:
      – SubjectFull: Hepatitis C treatment
        Type: general
      – SubjectFull: Intravenous drug abusers
        Type: general
      – SubjectFull: Hepatitis C prevention
        Type: general
      – SubjectFull: Antiviral agents
        Type: general
      – SubjectFull: Cost effectiveness
        Type: general
      – SubjectFull: Medical care costs
        Type: general
      – SubjectFull: Needle exchange programs
        Type: general
    Titles:
      – TitleFull: Cost‐effectiveness of scaling‐up HCV prevention and treatment in the United States for people who inject drugs.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Barbosa, Carolina
      – PersonEntity:
          Name:
            NameFull: Fraser, Hannah
      – PersonEntity:
          Name:
            NameFull: Hoerger, Thomas J.
      – PersonEntity:
          Name:
            NameFull: Leib, Alyssa
      – PersonEntity:
          Name:
            NameFull: Havens, Jennifer R.
      – PersonEntity:
          Name:
            NameFull: Young, April
      – PersonEntity:
          Name:
            NameFull: Kral, Alex
      – PersonEntity:
          Name:
            NameFull: Page, Kimberly
      – PersonEntity:
          Name:
            NameFull: Evans, Jennifer
      – PersonEntity:
          Name:
            NameFull: Zibbell, Jon
      – PersonEntity:
          Name:
            NameFull: Hariri, Susan
      – PersonEntity:
          Name:
            NameFull: Vellozzi, Claudia
      – PersonEntity:
          Name:
            NameFull: Nerlander, Lina
      – PersonEntity:
          Name:
            NameFull: Ward, John W.
      – PersonEntity:
          Name:
            NameFull: Vickerman, Peter
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2019
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 09652140
          Numbering:
            – Type: volume
              Value: 114
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Addiction
              Type: main
ResultId 1